Comparative Evaluation of A Partial Dopamine Agonist with A Preferential D2 and D3 Receptor Antagonist on Ethanol Induced Conditioned Place Preference in Mice

Author(s): Muhammad Akmal Yazdani, Muhammad Jamir Anwar, Bushra Parveen, Divya Vohora*.

Journal Name: Current Psychopharmacology

Volume 8 , Issue 1 , 2019

Submit Manuscript
Submit Proposal

Graphical Abstract:


Abstract:

Background: The role of dopamine receptor sub-families in the rewarding and reinforcing effects of drugs of abuse has been established in numerous studies.

Objectives: In view of the extensive role of mesolimbic dopaminergic transmission in rewarding and reinforcing effect of abused drugs including ethanol, the present study evaluated three mechanistically different drugs viz a partial dopaminergic agonist (PDA, aripiprazole), preferential D3 (mixed D2/D3) receptor antagonist (nafadotride), and a preferential D2 antagonist (haloperidol), on ethanol-induced conditioned place preference (CPP) in mice.

Method: The study was carried out in Swiss strain albino mice. Ethanol (20%, 2g/kg) was used to induce CPP in mice. After the acquisition of CPP, behavioral tests (elevated plus maze and locomotor activity) were conducted and effect of drugs on expression and on reinstatement (after extinction) was studied.

Results: We found that aripiprazole (1 and 2 mg/kg but not 0.5mg/kg), haloperidol (0.2 mg/kg), and nafadotride (4.5 mg/kg) administered for 1 week during the conditioning phase prevented acquisition, expression and reinstatement of ethanol-induced CPP. All the three drugs reduced the ethanol-induced locomotor stimulation and produced antianxiety effects in elevated plus maze following the acquisition of ethanol CPP.

Conclusion: Partial dopaminergic agonism by aripiprazole was found to be a better strategy for normalizing dopaminergic neurotransmission in alcoholics as seen in rodents.

Keywords: Aripiprazole, haloperidol, nafadotride, ethanol CPP, dopamine, agonism.

[1]
Soderpalm B, Ericson M. Neurocircuitry involved in the development of alcohol addiction: The dopamine system and its access points. Curr Top Behav Neurosci 2013; 13: 127-61.
[2]
Nestler EJ. Is there a common molecular pathway for addiction? Nat Neurosci 2005; 8: 1445-9.
[3]
Kenna GA. Pharmacotherapy of alcohol dependence: Targeting a complex disorder. Drug Discov Today Ther Strateg 2005; 2: 71-8.
[4]
Liu X, Jernigen C, Gharib M, Booth S, Caggiula AR, Sved AF. Effects of dopamine antagonists on drug cue-induced reinstatement of nicotine-seeking behavior in rats. Behav Pharmacol 2010; 21: 153-60.
[5]
Khaled MA, Pushparaj A, Di Ciano P, Diaz J, Le Foll B. Dopamine D3 receptors in the basolateral amygdala and the lateral habenula modulate cue-induced reinstatement of nicotine seeking. Neuropsychopharmacol 2014; 39(13): 3049-58.
[6]
Heidbreder CA, Gardner EL, Zheng Xiong Xi, et al. The role of central dopamine D3 receptors in drug addiction: A review of pharmacological evidence. Brain Res Rev 2005; 49: 77-105.
[7]
Manzanedo C, Aguilar MA, Rodriguez-Arias M, Minarro J. Effect of dopamine antagonists with different receptor blockade profiles on morphine-induced place preference in male mice. Behav Brain Res 2001; 121: 189-97.
[8]
Baladi MG, Newman AH, France CP. Feeding condition and the relative contribution of different dopamine receptor subtypes to the discriminative stimulus effects of cocaine in rats. Psychopharmacol 2014; 231: 581-91.
[9]
Rogowski A, Rokicki D, Kostowski W, Bienkowski P. Relationship between dopamine D2 receptor-associated responses and operant ethanol self-administration in the rat: A factor analysis. Alcohol Alcohol 2003; 38: 305-9.
[10]
Liu X, Weiss F. Reversal of ethanol-seeking behavior by D1 and D2 antagonists in an animal model of relapse: Differences in antagonist potency in previously ethanol-dependent versus non-dependent rats. J Pharmacol Exp Ther 2002; 300: 882-9.
[11]
Gremel CM, Cunningham CL. Involvement of amygdala dopamine and nucleus accumbens NMDA receptors in ethanol-seeking behavior in mice. Neuropsychopharmacol 2009; 34: 1443-53.
[12]
Moreira FA, Dalley JW. Dopamine receptor partial agonists and addiction. Eur J Pharmacol 2015; 752: 112-5.
[13]
Seeman P. Atypical antipsychotics: Mechanism of action. Can J Psychiatry 2002; Feb; 47(1): 27-38.
[14]
Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27(7): 1159-72.
[15]
Kapur S. Psychosis as a state of aberrant salience: A framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry 2003; 160(1): 13-23.
[16]
Li S, Zou Y, Liu L, Wu P, Lu L. Aripiprazole blocks reinstatement but not expression of morphine conditioned place preference in rats. Pharmacol Biochem Behav 2009; 92: 370-5.
[17]
Marinho EA, Oliveira-Lima AJ, Wuo-Silva R, et al. Selective action of an atypical neuroleptic on the mechanisms related to the development of cocaine addiction: A pre-clinical behavioural study. Int J Neuropsychopharmacol 2014; 17: 613-23.
[18]
Futamura T, Akiyama S, Sugino H, Forbes AD, McQuada R, Kikuchi T. Aripiprazole attenuates established behavioral sensitization induced by methamphetamine. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 1115-9.
[19]
Myrick H, Li X, Randall PK, Henderson S, Voronin K, Anton RF. The effect of aripiprazole on cue-induced brain activation and drinking parameters in alcoholics. J Clin Psychopharmacol 2010; 30: 365-72.
[20]
Burda-Malarz K, Kus K, Ratajczak P, Czubak A, Hardyk S, Nowakowska E. Evaluation of the antidepressant, anxiolytic and memory-improving efficacy of aripiprazole and fluoxetine in ethanol-treated rats. Drug Chem Toxicol 2014; 37: 281-9.
[21]
Vergne DE, Anton RF. Aripiprazole: A drug with a novel mechanism of action and possible efficacy for alcohol dependence. CNS Neurol Disord Drug Targets 2010; 9: 50-4.
[22]
Cunningham CL, Gremel CM, Groblewski PA. Drug-induced conditioned place preference and aversion in mice. Nat Protoc 2006; 4: 1662-70.
[23]
Bouthenet ML, Souil E, Martres MP, Sokoloff P, Giros B, Schwartz JC. Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: Comparison with dopamine D2 receptor mRNA. Brain Res 1991; 564: 203-19.
[24]
Houchi H, Babovic D, Pierrefiche O, Ledent C, Daoust M, Naassila M. CB1 receptor knockout mice display reduced ethanol-induced conditioned place preference and increased striatal dopamine D2 receptors. Neuropsychopharmacol 2005; 30: 339-49.
[25]
Ingman K, Kupila J, Hyytia P, Korpi ER. Effects of aripiprazole on alcohol intake in an animal model of high alcohol drinking. Alcohol 2006; 41: 391-8.
[26]
Dall’Olio R, Gaggi R, Voltattorni M, Tanda O, Gandolfi O. Nafadotride administration increases D1 and D1/D2 dopamine receptor mediated behaviours. Behav Pharmacol 2002; 13: 633-8.
[27]
Bharal N, Pillai KK, Vohora D. Effects of sparfloxacin on CNS functions and urinary hydroxyproline in mice. Pharmacol Res 2006; 54: 111-7.
[28]
Ali A, Ahmad FJ, Pillai KK, Vohora D. Evidence of the antiepileptic potential of amiloride with neuropharmacological benefits in rodent models of epilepsy and behavior. Epilepsy Behav 2004; 5: 322-8.
[29]
Aguilar MA, Rodriguez-Arias M, Minarro J. Neurobiological mechanisms of the reinstatement of drug-conditioned place preference. Brain Res Rev 2009; 59: 253-77.
[30]
Gonzales RA, Job MO, Doyon WM. The role of mesolimbic dopamine in the development and maintenance of ethanol reinforcement. Pharmacol Ther 2004; 103: 121-46.
[31]
Beninger RJ, Banasikowski TJ. Dopaminergic mechanism of reward-related incentive learning: focus on the dopamineD (3) receptor. Neurotox Res 2008; 14(1): 57-70.
[32]
Filip M, Papla I, Czepiel K. Role of D3 receptor in controlling the expression of cocaine sensitization in rats. Pol J Pharmacol 2002; 54: 687-91.
[33]
Duarte C, Biala G, Bihan CL, Hamon M, Theibot MH. Respective roles of dopamine D2 and D3 receptor in food seeking behavior in rats. Psychopharmacol 2003; 166: 19-32.
[34]
Vorel SR, Ashby Jr C.R., Paul M, Liu X, et al. Dopamine D3 receptor antagonism inhibits cocaine-seeking and cocaine-enhanced brain reward in rats. J Neurosci 2002; 22: 9595-603.
[35]
Ashby Jr C.R., Paul M, Gardener EL, Heidbreder CA, Hagan JJ. Acute administration of selective D3 receptor antagonist SB-277011-A blocks the acquisition and expression of the conditioned place preference response to heroin in male rats. Synapse 2003; 48: 154-6.
[36]
Jeanblanc J, He DY, McGough NNH, et al. The dopamine D3 receptor is part of a homeostatic pathway regulating ethanol consumption. J Neurosci 2006; 26: 1457-64.
[37]
Audinot V, Newman-Tancredi A, Gobert A, et al. A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194. J Pharmacol Exp Ther 1998; 287: 187-97.
[38]
Davies MA, Sheffler DJ, and Roth BL. Aripiprazole: A novel atypical antipsychotic drug with a uniquely robust pharmacology. CNS Drug Rev 2003; 28(8): 1400-11.
[39]
Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 2002; 441: 137-40.
[40]
Grunder G, Carlsson A, Wong DF. Mechanism of new antipsychotic medications: Occupancy is not just antagonism. Arch Gen Psychiatry 2003; 60: 974-7.
[41]
Feltenstein MW, Altar CA, See RE. Aripiprazole blocks reinstatement of cocaine seeking in an animal model of relapse. Biol Psychiatry 2007; 61: 582-90.
[42]
Janiri L, Martinotti G, Di Nicola M. Aripiprazole for relapse prevention and craving in alcohol-dependent subjects: Results from a pilot study. J Clin Psychopharmacol 2007; 27: 519-20.
[43]
Cunningham CL, Malott DH, Dickinson SD, Risinger FO. Haloperidol does not alter expression of ethanol-induced conditioned place preference. Behav Brain Res 1992; 50: 1-5.
[44]
Ohlsen RI, Pilowsky LS. The place of partial agonism in psychiatry: Recent developments. J Psychopharmacol 2005; 19: 408-13.
[45]
Pae CU, Serretti A, Patkar AA, Masand PS. Aripiprazole in the treatment of depressive and anxiety disorders: A review of current evidence. CNS Drugs 2008; 22: 367-88.
[46]
Biojone C, Casarotto PC, Resstel LB, Zangrossi Jr H., Guimares FS, Moreira FA. Anti-aversive effects of the atypical antipsychotic, aripiprazole, in animal models of anxiety. J Psychopharmacol 2011; 25: 801-7.
[47]
Richtand NM, Logue AD, Welge JA, et al. The dopamine D3 receptor antagonist nafadotride inhibit development of locomotor sensitization to amphetamine. Brain Res 2000; 867: 239-42.
[48]
Leite JV, Guimaraes FS, Moreira FA. Aripiprazole, an atypical antipsychotic, prevents the motor hyperactivity induced by psychotomimetics and psychostimulants in mice. Eur J Pharmacol 2008; 578: 222-7.


Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 8
ISSUE: 1
Year: 2019
Page: [55 - 63]
Pages: 9
DOI: 10.2174/2211556007666180705130103

Article Metrics

PDF: 23